Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Unknown 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 2Breast Neoplasms 2Pancreatic Neoplasms 1Heart Failure 1Cardiotoxicity 1Atherosclerosis 1

Interventions

Exercise 19Drug Therapy 18pembrolizumab 13Capecitabine 11Blood Specimen Collection 11Surveys and Questionnaires 10Radiotherapy 10Paclitaxel 9Dexamethasone 9Nivolumab 8Standard of Care 7Oxaliplatin 7Fluorouracil 7Erlotinib Hydrochloride 7apatinib 6Interviews as Topic 6Gemcitabine 6Control Groups 6Cisplatin 6Therapeutics 5Neoadjuvant Therapy 5Mindfulness-Based Cognitive Therapy 5Metformin 5Injections 5Everolimus 5Docetaxel 5Cyclophosphamide 5Bevacizumab 5sintilimab 4atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Neoplasms × Hydroxymethylglutaryl-CoA Reductase Inhibitors × Clear all
NCT05976893 2023-08-04

Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

Xinjiang Medical University

Phase 4 Unknown
620 enrolled

Neoplasms, Atherosclerosis

NCT03186404 2022-02-08

SPARE-HF

University Health Network, Toronto

Phase 2 Unknown
112 enrolled

Heart Failure, Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡